Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Other Operating Expenses (2023 - 2025)

Spyre Therapeutics (SYRE) has disclosed Other Operating Expenses for 4 consecutive years, with $11.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Operating Expenses changed N/A year-over-year to $11.6 million, compared with a TTM value of $21.6 million through Dec 2025, changed N/A, and an annual FY2025 reading of $10.0 million, changed N/A over the prior year.
  • Other Operating Expenses was $11.6 million for Q3 2025 at Spyre Therapeutics, up from $10.0 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $130.5 million in Q2 2023 and bottomed at -$14.9 million in Q3 2023.